TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17621415

Group type: EXPERIMENTAL
Intervention: Sulindac (200 mg/day, 100 mg twice a day; n = 16 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 24 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sulindac group
Number of subjects: 40
Study: 15665025

Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (AH)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no laser-assisted hatching)
Number of subjects: 160
Study: 11990441

Group type: EXPERIMENTAL
Intervention: Enamel matrix protein derivative (EMD) combined with bioactive glass (BG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bioactive glass (BG) alone
Number of subjects: 28
Study: 9440402

Group type: EXPERIMENTAL
Intervention: Preliminary notification
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Short length of the questionnaire
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Combination of preliminary notification, short questionnaire, and no mention of telephone contact
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Combination of no preliminary notification, long questionnaire, and mention of telephone contact
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Demographic characteristics (young age, male sex, urban residence)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Old age
Number of subjects: 2000
Study: 10781270

Group type: EXPERIMENTAL
Intervention: Hypnotic state
Number of subjects: 11

Group type: COMPARATOR
Intervention: Resting state
Number of subjects: 11

Group type: COMPARATOR
Intervention: Mental imagery
Number of subjects: 11
Study: 1991261

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus fluoxymesterone (TAM + FLU)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) alone
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus fluoxymesterone (TAM + FLU) in patients aged 65 or older with ER of 10 or greater
Number of subjects: 238
Study: 6185212

Group type: EXPERIMENTAL
Intervention: CHOP-BCG
Number of subjects: 652

Group type: COMPARATOR
Intervention: CHOP-bleomycin
Number of subjects: 652

Group type: COMPARATOR
Intervention: COP-bleomycin
Number of subjects: 652
Study: 31564241

Group type: EXPERIMENTAL
Intervention: Enhanced oral healthcare
Number of subjects: 325

Group type: COMPARATOR
Intervention: Usual oral healthcare
Number of subjects: 325
Study: 30584118

Group type: EXPERIMENTAL
Intervention: Upper cervical and upper thoracic spine mobilization
Number of subjects: 31

Group type: COMPARATOR
Intervention: Deep cervical flexors exercise (DCFE)
Number of subjects: 31
Study: 27613901

Group type: EXPERIMENTAL
Intervention: mHealth reinforcement
Number of subjects: 90

Group type: COMPARATOR
Intervention: mHealth monitoring
Number of subjects: 90
Study: 27290982

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (group D; n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol (group P; n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 27359067

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (4000 IU daily) for 2 months prior to surgery
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo for 2 months prior to surgery
Number of subjects: 27
Study: 23895860

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 µg/kg loading dose, 0.3 µg·kg(‐1)·h(‐1) maintenance dose)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 22
Study: 22180397

Group type: EXPERIMENTAL
Intervention: Dose-dense weekly paclitaxel 80 mg/m(2) plus 3-weekly carboplatin AUC 6
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3-weekly paclitaxel/carboplatin
Number of subjects: 0
Study: 19210629

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315

Group type: COMPARATOR
Intervention: Drug
Number of subjects: 315
Study: 17116705

Group type: EXPERIMENTAL
Intervention: Chili (4.2 g dry powder, 25 mg polyphenols as gallic acid equivalents)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Turmeric (0.5 g dry powder, 50 mg polyphenols as gallic acid equivalents)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chili (4.2 g dry powder)
Number of subjects: 10
Study: 14742340

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% solution (0.7 ml x kg(‐1))
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375% solution (0.7 ml x kg(‐1))
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fascia iliaca compartment block
Number of subjects: 6
Study: 11728893

Group type: EXPERIMENTAL
Intervention: Peer education program (West African Youth Initiative)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10795779

Group type: EXPERIMENTAL
Intervention: Whole milk
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sport drink A (carbohydrate and electrolytes)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sport drink B (carbohydrate, fat, and protein)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Skim milk
Number of subjects: 28

Group type: COMPARATOR
Intervention: Water
Number of subjects: 28
Study: 10188789

Group type: EXPERIMENTAL
Intervention: WAL 2014 (40 mg and higher)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: WAL 2014 (80 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: WAL 2014 (120 mg and 160 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: WAL 2014 (100 mg-140 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: WAL 2014 (100 mg upwards)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: WAL 2014 (40, 60, 80, 100, and 140 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: WAL 2014
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2165800

Group type: EXPERIMENTAL
Intervention: Sodium iso‐nonanoyl oxybenzene sulphonate (SINOS) 0.01‐100 micrograms
Number of subjects: 9

Group type: COMPARATOR
Intervention: Linear alkyl benzene sulphonate (LAS) 0.01‐100 micrograms
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sodium iso‐nonanoyl oxybenzene sulphonate (SINOS)
Number of subjects: 9
Study: 653534

Group type: EXPERIMENTAL
Intervention: Pyridoxine administration in normal postpartum women
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Pyridoxine administration in patients with chlorpromazine-induced hyperprolactinaemia
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (normal postpartum women)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (patients with chlorpromazine-induced hyperprolactinaemia)
Number of subjects: 2
Study: 31055009

Group type: EXPERIMENTAL
Intervention: Modelling enjoyment (mention of carrot sticks that characters like)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Modelling intake (mention of carrot sticks that all characters ate)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Modelling enjoyment
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control (no mention of carrot sticks)
Number of subjects: 155
Study: 29186759

Group type: EXPERIMENTAL
Intervention: 4000 IU of vitamin D
Number of subjects: 90
Study: 26159452

Group type: EXPERIMENTAL
Intervention: Tweeting arm (intervention group) - three tweets daily using Hootsuite with specific content related to the systematic reviews.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Non-tweeting arm (control group) - no tweets.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Tweeting arm (intervention group)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Non-tweeting arm (control group)
Number of subjects: 170
Study: 23864583

Group type: EXPERIMENTAL
Intervention: Race-conscious blacks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Race-conscious whites
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-race-conscious blacks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-race-conscious whites
Number of subjects: 100
Study: 22001341

Group type: EXPERIMENTAL
Intervention: Vibration-assisted anesthesia during BTX‐A injections
Number of subjects: 50

Group type: COMPARATOR
Intervention: BTX‐A injections alone (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vibration-assisted anesthesia
Number of subjects: 50
Study: 19441605

Group type: EXPERIMENTAL
Intervention: loratadine-montelukast (10 mg/10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: phenylephrine (10 mg)
Number of subjects: 0
Study: 16620740

Group type: EXPERIMENTAL
Intervention: Experienced drivers
Number of subjects: 2

Group type: COMPARATOR
Intervention: Inexperienced drivers
Number of subjects: 2
Study: 15262244

Group type: EXPERIMENTAL
Intervention: NASHA
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study: 11515928

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized clinical trials (RCTs)
Number of subjects: 0
Study: 8993254

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 20 mg/kg body weight (S group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (C group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (S group)
Number of subjects: 24
Study: 10419708

Group type: EXPERIMENTAL
Intervention: HAI with 5-FUDR (Protocol A)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: HAI with 5-FUDR + i.v. (Protocol B)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: HAI with 5-FU + FA (Protocol C)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: HAI with MFFM (Protocol D)
Number of subjects: 168

Group type: COMPARATOR
Intervention: HAI with 5-FUDR or 5-FU + FA (Control)
Number of subjects: 168
Study: 2115819

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 414557

Group type: EXPERIMENTAL
Intervention: Iodoxamate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iodipamide
Number of subjects: 0
Study: 30859204

Group type: EXPERIMENTAL
Intervention: 18S rDNA copy number quartiles
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 5.8S rDNA copy number quartiles
Number of subjects: 229
Study: 28688667

Group type: COMPARATOR
Intervention: ICG alone
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: ICG and blue dye
Number of subjects: 127
Study: 25375979

Group type: EXPERIMENTAL
Intervention: TNF‐α (12 ng/kg/h) infusion
Number of subjects: 16
Study: 23971620

Group type: EXPERIMENTAL
Intervention: ω3 PUFA (n=7)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (n=9)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison of ω3 PUFA and Placebo
Number of subjects: 16
Study: 22256576

Group type: EXPERIMENTAL
Intervention: FA plus TH (Flurbiprofen axetil 4 mg kg‐1 . 24 hr‐1 and Tramadol hydrochloride 2 mg kg‐1 . 24 hr‐1 after bolus injection of FA 50 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: FA alone (Flurbiprofen axetil 4 mg kg‐1 . 24 hr‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 50
Study: 19565736

Group type: EXPERIMENTAL
Intervention: Pricking blood therapy combined with ultraviolet irradiation
Number of subjects: 130

Group type: COMPARATOR
Intervention: Aciclovir and other western medicine
Number of subjects: 130
Study: 16455427

Group type: EXPERIMENTAL
Intervention: Early group (within 5 days after embolism)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Late group (more than 5 days after embolism)
Number of subjects: 39
Study: 15236807

Group type: EXPERIMENTAL
Intervention: Gradual withdrawal treatment approaches
Number of subjects: 76
Study: 11238433

Group type: EXPERIMENTAL
Intervention: Mass media health education campaign for TB control
Number of subjects: 0
Study: 8981389

Group type: EXPERIMENTAL
Intervention: mCPP (0.1 mg/kg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.5 mg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 26
Study: 8513291

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (200 mg starting dose, followed by 100 mg weekly)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2878867

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg p.o.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg p.o.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg sublingually)
Number of subjects: 8
Study: 31233269

Group type: EXPERIMENTAL
Intervention: Positive framing
Number of subjects: 96

Group type: COMPARATOR
Intervention: Negative framing
Number of subjects: 96
Study: 30053278

Group type: EXPERIMENTAL
Intervention: 10 µg 25(OH)D3 daily
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 20 µg vitamin D3 daily
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 26341679

Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding (NAM) performed by 1 month of age (group I, n = 50)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding (NAM) performed at 1 to 6 months of age (group II, n = 50)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding (NAM) performed at 6 months to 1 year of age (group III, n = 50)
Number of subjects: 150
Study: 25093275

Group type: EXPERIMENTAL
Intervention: 135 g serving of lean beef (tinned meat) providing 20 g of protein and 1.7 g of fat after resistance training.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no supplementation).
Number of subjects: 26
Study: 22167633

Group type: EXPERIMENTAL
Intervention: Visual education by videotape (video group)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (only information given)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Adherent patients using CPAP effectively
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Duration of CPAP use
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Adverse effects (mask intolerance, choking, noise, nasal congestion)
Number of subjects: 133
Study: 21111314

Group type: EXPERIMENTAL
Intervention: Ultraviolet-A/riboflavin CXL therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Riboflavin alone without epithelial debridement (Control)
Number of subjects: 0
Study: 18515652

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) for 3 months
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Internal stretch fraction (ISF)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Internal stretch fraction (ISF) > 0.4
Number of subjects: 19
Study: 15837100

Group type: EXPERIMENTAL
Intervention: 500 mg of T. arjuna
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12888363

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (48‐54 Gy)
Number of subjects: 1187

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 1187
Study: 10533698

Group type: EXPERIMENTAL
Intervention: Nonlinear mixed‐effects model (Emax) with interindividual and interoccasion variability (IOV)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Linear mixed‐effects model
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Monte Carlo simulations based on a similar study design
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nonlinear mixed‐effects model
Number of subjects: 37
Study: 8691512

Group type: EXPERIMENTAL
Intervention: Whole Blood Autotransfusion (WBA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cell Separation (CS)
Number of subjects: 32
Study: 1881729

Group type: EXPERIMENTAL
Intervention: Pediatric Home Care (PHC) program
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 219
Study: 7049708

Group type: EXPERIMENTAL
Intervention: Ticrynafen
Number of subjects: 11

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 11
Study: 31830078

Group type: EXPERIMENTAL
Intervention: Peer-led interpersonal communication (IPC) intervention
Number of subjects: 2430

Group type: COMPARATOR
Intervention: Control (mass media campaign only)
Number of subjects: 2430
Study: 30413379

Group type: EXPERIMENTAL
Intervention: Anthracycline group (5-fluorouracil, epirubicin, cyclophosphamide followed by paclitaxel and carboplatin)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Non-anthracycline group (paclitaxel and carboplatin)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Anthracycline group
Number of subjects: 438

Group type: COMPARATOR
Intervention: Non-anthracycline group
Number of subjects: 438
Study: 26806732

Group type: EXPERIMENTAL
Intervention: Annular electrode lacrimal duct reconstruction
Number of subjects: 119

Group type: COMPARATOR
Intervention: No annular electrode lacrimal duct reconstruction (control)
Number of subjects: 119
Study: 24766973

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily (15 mg if creatinine clearance is 30‐49 mL/min)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Dose-adjusted vitamin K antagonists (VKAs; INR 2.0‐3.0)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Rivaroxaban or VKA administered for 21 to 56 days before cardioversion
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Rivaroxaban or VKA administered for 6 weeks postcardioversion
Number of subjects: 1500
Study: 22963001

Group type: COMPARATOR
Intervention: Sildenafil (pharmacologic intervention)
Number of subjects: 106
Study: 19286123

Group type: EXPERIMENTAL
Intervention: BART intervention (8-week community-based translation)
Number of subjects: 246

Group type: COMPARATOR
Intervention: General health education control group
Number of subjects: 246
Study: 17460710

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15366799

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 400
Study: 11583728

Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg, twice daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pentoxifylline (400 mg, twice daily)
Number of subjects: 32
Study: 10741176

Group type: EXPERIMENTAL
Intervention: 0.02% mitomycin C solution
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (no mitomycin C)
Number of subjects: 130
Study: 8016037

Group type: EXPERIMENTAL
Intervention: Health promotion interventions at 16 sites
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sites changing from unrestrictive to restrictive policies
Number of subjects: 32

Group type: COMPARATOR
Intervention: Restrictive smoking policies
Number of subjects: 32
Study: 2807523

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (5 x 10^8 organisms)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 131976

Group type: EXPERIMENTAL
Intervention: Hydrocortisone hemisuccinate (steroid group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Non-steroid treatment (control group)
Number of subjects: 98
Study: 30374746

Group type: EXPERIMENTAL
Intervention: Instruction to imagine themselves in the situation of a social benefit claimant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group instructed to answer honestly
Number of subjects: 60
Study: 28527545

Group type: EXPERIMENTAL
Intervention: Relief band using transcutaneous electrical nerve stimulation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Wrist band using acupressure
Number of subjects: 54
Study: 26413979

Group type: EXPERIMENTAL
Intervention: GD Choice
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 68
Study: 23336549

Group type: EXPERIMENTAL
Intervention: Problem-solving intervention (five weekly 90-minute group sessions)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 173
Study: 21700924

Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CIMT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hand‐arm intensive bimanual therapy (HABIT)
Number of subjects: 42
Study: 18853558

Group type: EXPERIMENTAL
Intervention: Parents of monozygotic twins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control parents (non-twin siblings)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twins' parents with inverted faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twins' parents with familiar faces
Number of subjects: 0
Study: 16625986

Group type: EXPERIMENTAL
Intervention: Sublingual desmopressin 160 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sublingual desmopressin 240 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sublingual desmopressin 320 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sublingual desmopressin (all doses)
Number of subjects: 16
Study: 15598859

Group type: EXPERIMENTAL
Intervention: Deadline (n = 126)
Number of subjects: 246

Group type: COMPARATOR
Intervention: No Deadline (n = 120)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Deadline
Number of subjects: 246

Group type: COMPARATOR
Intervention: No Deadline
Number of subjects: 246
Study: 11281616

Group type: EXPERIMENTAL
Intervention: Relaxation with guided imagery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Incremental exercise to fatigue
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cycling at 30% or 60% of maximum heart rate
Number of subjects: 20
Study: 9154395

Group type: EXPERIMENTAL
Intervention: 1% Lamisil emulsion gel
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 83
Study: 7895384

Group type: COMPARATOR
Intervention: Intranasal sodium cromoglycate (single dose)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intranasal sodium cromoglycate (3-week course)
Number of subjects: 9
Study: 3266156

Group type: EXPERIMENTAL
Intervention: Spironolactone (100‐200 mg/day)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (50‐100 mg/day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 88
Study: 31139889

Group type: EXPERIMENTAL
Intervention: Total protein intake
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Animal protein intake
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Red meat intake (high tertile)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Total or relative protein intake, or ratio of animal to plant protein
Number of subjects: 79